HLS Therapeutics Q2 2024 Earnings Report C$3.62 +0.02 (+0.56%) (As of 12/18/2024 05:28 PM ET) Earnings HistoryForecast HLS Therapeutics EPS ResultsActual EPS-C$0.25Consensus EPS -C$0.25Beat/MissMet ExpectationsOne Year Ago EPSN/AHLS Therapeutics Revenue ResultsActual Revenue$19.87 millionExpected Revenue$19.25 millionBeat/MissBeat by +$620.00 thousandYoY Revenue GrowthN/AHLS Therapeutics Announcement DetailsQuarterQ2 2024Date8/8/2024TimeN/AConference Call ResourcesHLS Earnings History Uncover the Top Gold Stock of the Bull Market (Ad)Gold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Click here to see how this opportunity could transform your portfolio. HLS Therapeutics Earnings HeadlinesHLS Therapeutics (TSE:HLS) Shares Down 0.3% - Here's WhyDecember 14, 2024 | americanbankingnews.comOptimistic Buy Rating for HLS Therapeutics Despite Revenue ChallengesNovember 10, 2024 | markets.businessinsider.comWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.December 19, 2024 | Behind the Markets (Ad)HLS Therapeutics Third Quarter 2024 Earnings: Misses ExpectationsNovember 8, 2024 | finance.yahoo.comHLS Therapeutics Inc (HLTRF) Q3 2024 Earnings Call Highlights: Strategic Debt Reduction and ...November 8, 2024 | finance.yahoo.comHLS Therapeutics Inc (TSX:HLS) Q3 2024: Everything You Need To Know Ahead Of EarningsNovember 6, 2024 | finance.yahoo.comSee More HLS Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like HLS Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HLS Therapeutics and other key companies, straight to your email. Email Address About HLS TherapeuticsHLS Therapeutics (TSE:HLS), a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.View HLS Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
